Riccardo Ronco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Riccardo Ronco has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Adriana Rebelo
Dr John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics University of Miami Miller School of Medicine Miami Florida USA
1 shared publication- Alessia Mongelli
Unit of Medical Genetics and Neurogenetics Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy
1 shared publication Alex M. Rossor
Department of Neuromuscolar Diseases UCL Queen Square Institute of Neurology London UK
1 shared publication- Andrea Cortese
Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology , London WC1N 3BG
1 shared publication - Andrea Quatrana
Unit of Muscular and Neurodegenerative Diseases Bambino Gesù Children's Hospital, IRCCS Rome Italy
1 shared publication - Anna Castaldo
Unit of Medical Genetics and Neurogenetics Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy
1 shared publication
Latest Publications
- 9 November 2026
- Published by Wiley in Movement Disorders
Blood‐Based Lipid Peroxidation and Ferroptosis‐Related Markers in Friedreich's Ataxia
Background: Friedreich's ataxia (FRDA) is a neurodegenerative disease caused by reduced levels the mitochondrial frataxin protein. Systemic oxidative stress and iron‐dependent lipid peroxidation, commonly associated with ferroptosis, have a critical role in disease pathogenesis. Objectives: We aimed to evaluate longitudinal changes of blood‐based indexes of oxidative stress and ferroptosis‐related molecules in adults and children with FRDA. Methods: We measured plasma levels of 4‐hydroxyl‐2‐nonenals (4‐HNE) and hydroxyeicosatetraenoic acid (15‐HETE), and blood concentration of glutathione (GSH), glutathione disulfide (GSSG), in 62 FRDA patients (48 adults and 14 children) and 63 age matched healthy controls. mRNA levels of major genes targeting the nuclear factor erythroid 2‐related factor 2 (NRF2) were also evaluated. Peripheral concentrations of lipid peroxidation markers and ferroptosis‐related molecules were correlated with age, disease duration, and severity of ataxia signs. Clinical and biochemical evaluations were performed at baseline and at 1‐year follow‐up. Results: FRDA patients had significantly increased levels of 4‐HNE and GSSG and decreased levels of GSH, compared to controls. Children with FRDA had lower levels of glutathione peroxidase 4 ( GPX4 ) mRNA than adult patients. At 1‐year follow up, plasma 4‐HNE levels remained stable, and blood GPX4 mRNA increased only in adult patient cohort. GPX4 correlated with age, disease duration, and clinical scores. Conclusions: We provide preliminary evidence of defective GPX4 expression in the early phase of the disease. Our data suggest that GPX4 may represent a biomarker for disease progression and a possible candidate target for therapeutic strategies. © 2026 International Parkinson and Movement Disorder Society.
- 9 November 2026
- Published by Wiley in Movement Disorders
Blood‐Based Lipid Peroxidation and Ferroptosis‐Related Markers in Friedreich's Ataxia
Background: Friedreich's ataxia (FRDA) is a neurodegenerative disease caused by reduced levels the mitochondrial frataxin protein. Systemic oxidative stress and iron‐dependent lipid peroxidation, commonly associated with ferroptosis, have a critical role in disease pathogenesis. Objectives: We aimed to evaluate longitudinal changes of blood‐based indexes of oxidative stress and ferroptosis‐related molecules in adults and children with FRDA. Methods: We measured plasma levels of 4‐hydroxyl‐2‐nonenals (4‐HNE) and hydroxyeicosatetraenoic acid (15‐HETE), and blood concentration of glutathione (GSH), glutathione disulfide (GSSG), in 62 FRDA patients (48 adults and 14 children) and 63 age matched healthy controls. mRNA levels of major genes targeting the nuclear factor erythroid 2‐related factor 2 (NRF2) were also evaluated. Peripheral concentrations of lipid peroxidation markers and ferroptosis‐related molecules were correlated with age, disease duration, and severity of ataxia signs. Clinical and biochemical evaluations were performed at baseline and at 1‐year follow‐up. Results: FRDA patients had significantly increased levels of 4‐HNE and GSSG and decreased levels of GSH, compared to controls. Children with FRDA had lower levels of glutathione peroxidase 4 ( GPX4 ) mRNA than adult patients. At 1‐year follow up, plasma 4‐HNE levels remained stable, and blood GPX4 mRNA increased only in adult patient cohort. GPX4 correlated with age, disease duration, and clinical scores. Conclusions: We provide preliminary evidence of defective GPX4 expression in the early phase of the disease. Our data suggest that GPX4 may represent a biomarker for disease progression and a possible candidate target for therapeutic strategies. © 2026 International Parkinson and Movement Disorder Society.
- Open Access
- 29 September 2023
- Published by Wiley in European Journal of Neurology
- Vol. 31 (1)
Mutations in alpha‐B‐crystallin cause autosomal dominant axonal Charcot–Marie–Tooth disease with congenital cataracts
Background and purpose: Mutations in the alpha‐B‐crystallin (CRYAB) gene have initially been associated with myofibrillar myopathy, dilated cardiomyopathy and cataracts. For the first time, peripheral neuropathy is reported here as a novel phenotype associated with CRYAB.Methods: Whole‐exome sequencing was performed in two unrelated families with genetically unsolved axonal Charcot–Marie–Tooth disease (CMT2), assessing clinical, neurophysiological and radiological features.Results: The pathogenic CRYAB variant c.358A>G;p.Arg120Gly was segregated in all affected patients from two unrelated families. The disease presented as late onset CMT2 (onset over 40 years) with distal sensory and motor impairment and congenital cataracts. Muscle involvement was probably associated in cases showing mild axial and diaphragmatic weakness. In all cases, nerve conduction studies demonstrated the presence of an axonal sensorimotor neuropathy along with chronic neurogenic changes on needle examination.Discussion: In cases with late onset autosomal dominant CMT2 and congenital cataracts, it is recommended that CRYAB is considered for genetic testing. The identification of CRYAB mutations causing CMT2 further supports a continuous spectrum of expressivity, from myopathic to neuropathic and mixed forms, of a growing number of genes involved in protein degradation and chaperone‐assisted autophagy.
- 29 September 2023
- Published by Wiley in European Journal of Neurology
- Vol. 31 (1)
Open AccessMutations in alpha‐B‐crystallin cause autosomal dominant axonal Charcot–Marie–Tooth disease with congenital cataracts
Background and purpose: Mutations in the alpha‐B‐crystallin (CRYAB) gene have initially been associated with myofibrillar myopathy, dilated cardiomyopathy and cataracts. For the first time, peripheral neuropathy is reported here as a novel phenotype associated with CRYAB.Methods: Whole‐exome sequencing was performed in two unrelated families with genetically unsolved axonal Charcot–Marie–Tooth disease (CMT2), assessing clinical, neurophysiological and radiological features.Results: The pathogenic CRYAB variant c.358A>G;p.Arg120Gly was segregated in all affected patients from two unrelated families. The disease presented as late onset CMT2 (onset over 40 years) with distal sensory and motor impairment and congenital cataracts. Muscle involvement was probably associated in cases showing mild axial and diaphragmatic weakness. In all cases, nerve conduction studies demonstrated the presence of an axonal sensorimotor neuropathy along with chronic neurogenic changes on needle examination.Discussion: In cases with late onset autosomal dominant CMT2 and congenital cataracts, it is recommended that CRYAB is considered for genetic testing. The identification of CRYAB mutations causing CMT2 further supports a continuous spectrum of expressivity, from myopathic to neuropathic and mixed forms, of a growing number of genes involved in protein degradation and chaperone‐assisted autophagy.